News and Events

Stay up-to-date on the latest news about bleeding disorders, treatments, and more from CSL Behring, as well as upcoming educational and community events in which CSL Behring is participating.


To stay informed about the latest news in bleeding disorders, you or your patients may be interested in attending the conferences and meetings listed below.* CSL Behring will be participating in all of these events, so please stop by our exhibit booth and get information on Humate-P, speak with a CSL Behring representative, or obtain brochures.

Hemophilia Federation of America (HFA)
HFA Symposium

Hemostasis and Thrombosis Research Society (HTRS)
Thrombosis & Hemostasis Summit of North America

International Society of Thrombosis and Haemostasis (ISTH)
Annual SSC Meeting

National Hemophilia Foundation
Annual Meeting

American Society of Hematology (ASH)
ASH Annual Meeting and Exposition

Most local hemophilia chapters have a Web site, which typically includes a calendar of events. To find a chapter near you, go to the National Hemophilia Foundation Web site at:

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P® is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations. Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with risk factors for thrombosis.

Humate-P is derived from human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions (reported by >5% of subjects) were allergic/anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, and edema. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

The information provided here is primarily intended for use by physicians and other healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.

Treatment for VWD patients

© CSL Behring 2019. The product information presented on this site is intended for US residents only. 11-HUM-082